Who are EyePoint, Inc.'s main suppliers?

EyePoint, Inc. (EYPT) key suppliers include: FARMABIOS, SWK-FUNDING-LLC, THIRD-PARTY-SUPPLIER, ANI Pharmaceuticals, Inc., ANI Pharmaceuticals, Inc.. View the full supplier network at chainsifter.com/chain/EYPT.

Who are EyePoint, Inc.'s major customers?

EyePoint, Inc. (EYPT) key customers include: OCULAR-THERAPEUTIX-INC, PARTNER, ANI Pharmaceuticals, Inc., ANI Pharmaceuticals, Inc., Ocular Therapeutix, Inc. and 6 more. View the full customer network at chainsifter.com/chain/EYPT.

What sector is EyePoint, Inc. in?

EyePoint, Inc. (EYPT) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

EyePoint, Inc. Supplier List (EYPT): 5 Verified Suppliers

5Suppliers

11Customers

2Debt Items

6Related Chains

Source-Backed Evidence Depth

EyePoint, Inc. (EYPT) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

19Total relationships

4Distinct source URLs

8High confidence

0.769Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

EyePoint, Inc. Suppliers

Ticker	Name	Confidence	Evidence
FARMABIOS	FARMABIOS	90%	We source the API from Farmabios, needles from a third party supplier and various other raw materials and components for YUTIQ ® from additional third-party vendors.
SWK-FUNDING-LLC	SWK-FUNDING-LLC	90%	Pursuant to a royalty purchase agreement (RPA) with SWK Funding LLC (SWK), the Company sold its right to receive royalty payments on future sales of products subject to a licensing and development ag…
THIRD-PARTY-SUPPLIER	THIRD-PARTY-SUPPLIER	90%	We source the API from Farmabios, needles from a third party supplier and various other raw materials and components for YUTIQ ® from additional third-party vendors.
ANIP	ANI Pharmaceuticals, Inc.	72%	Reciprocal relationship from ANIP graph: Reciprocal relationship from EYPT graph: financial statements. It is important that the discussion of our operating results that follows be read in conjunctio…
ANIP	ANI Pharmaceuticals, Inc.	72%	financial statements. It is important that the discussion of our operating results that follows be read in conjunction with the critical accounting policies discussed below. Revenue Recognition Reven…

EyePoint, Inc. Customers

Ticker	Name	Confidence	Evidence
OCULAR-THERAPEUTIX-INC	OCULAR-THERAPEUTIX-INC	90%	The Complaint alleges, among other things, Defendant's dissemination of false or misleading representations of fact concerning the Company and the clinical results of the Company's lead product candi…
PARTNER	PARTNER	90%	we are supplying such product to our partner pursuant to our agreement with them.
ANIP	ANI Pharmaceuticals, Inc.	72%	financial statements. It is important that the discussion of our operating results that follows be read in conjunction with the critical accounting policies discussed below. Revenue Recognition Reven…
ANIP	ANI Pharmaceuticals, Inc.	72%	Reciprocal relationship from ANIP graph: Reciprocal relationship from EYPT graph: Reciprocal relationship from ANIP graph: Reciprocal relationship from EYPT graph: Reciprocal relationship from ANIP g…
OCUL	Ocular Therapeutix, Inc.	72%	Reciprocal relationship from OCUL graph: Reciprocal relationship from EYPT graph: Reciprocal relationship from OCUL graph: Reciprocal relationship from EYPT graph: nications by third parties, includi…
OCUL	Ocular Therapeutix, Inc.	72%	nications by third parties, including competitors, whether accurate or inaccurate, that may be perceived as negative with respect to us, our business, our product candidates, our preclinical and clin…
ALIMERA-SCIENCES-INC	ALIMERA-SCIENCES-INC	62%	mortization and accretion amounts are included in interest and other income, net in the consolidated statements of comprehensive loss. The cost of marketable securities sold is determined by the spec…
GENUS-MEDICAL-TECHNOLOGIES-LLC	GENUS-MEDICAL-TECHNOLOGIES-LLC	62%	resently restrict imports of products from countries where they may be sold at lower prices than in the U.S. Third-party payors often rely upon Medicare coverage policy and payment limitations in set…
NASDAQ-STOCK-MARKET-LLC	NASDAQ-STOCK-MARKET-LLC	62%	which we or our licensees may obtain regulatory approval, satisfying any post-marketing requirements and obtaining reimbursement for our products from private insurance or government payors. We do no…
ONCOSIL-MEDICAL-LTD	ONCOSIL-MEDICAL-LTD	62%	mortization and accretion amounts are included in interest and other income, net in the consolidated statements of comprehensive loss. The cost of marketable securities sold is determined by the spec…
SWK-FUNDING-LLC	SWK-FUNDING-LLC	62%	mortization and accretion amounts are included in interest and other income, net in the consolidated statements of comprehensive loss. The cost of marketable securities sold is determined by the spec…

EyePoint, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
EYPT-DEBT-9417	Warrants outstanding: 12.33	90%	xbrl warrant detail from xbrl 2024-12-31.
EYPT-DEBT	Debt stack $17.6M	90%	Market cache reports total debt of $17.6M.

EyePoint, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for EyePoint, Inc..

EyePoint, Inc. Ownership

Holder	Name	Confidence	Evidence
EYPT-OWNER-SUVRETTA-CAPITAL-MANAGEMENT-LLC	SUVRETTA CAPITAL MANAGEMENT, LLC	90%	13F overlay lists SUVRETTA CAPITAL MANAGEMENT, LLC as top holder; 192 tracked holders.

EyePoint, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
KLRS	Kalaris Therapeutics, Inc.	100.00	2
EMMA	Emmaus Life Sciences, Inc.	50.00	2
CELG-RI	BRISTOL MYERS SQUIBB CO	50.00	2
IRD	Opus Genetics, Inc.	50.00	2
ANIP	ANI Pharmaceuticals, Inc.	38.88	1	['customer', 'supplier']
OCUL	Ocular Therapeutix, Inc.	38.88	1	['customer']

EyePoint, Inc. Supply Chain